Ruikang Pharmaceutical released its 2026 interim report, with net profit attributable to the parent company of 11.1353 million yuan, down 38.70% from the same period last year. Total operating revenue was 3.415 billion yuan, down 3.63% year on year. Net cash inflow from operating activities was 48.7179 million yuan, down 28.24% year on year. The company's latest asset-liability ratio was 65.82%, gross margin was 11.37%, return on equity was 0.21%, and diluted earnings per share was 0.01 yuan.
Shandong Realcan Pharmaceutical Co LtdNet profit fell 38.70% year on year in the interim report.
